Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free HALO Stock Alerts

HaloSource (HALO) Competitors

HaloSource logo
Compare

HALO vs. PXS, MXC, RGT, CEL, and IDP

Should you buy HaloSource stock or one of its competitors? HaloSource's main competitors and comparable companies include Provexis (PXS), Argent BioPharma (MXC), Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), and InnovaDerma (IDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HaloSource compare to Provexis?

HaloSource (LON:HALO) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

HaloSource has a net margin of 0.00% compared to Provexis' net margin of -69.30%. HaloSource's return on equity of 0.00% beat Provexis' return on equity.

Company Net Margins Return on Equity Return on Assets
HaloSourceN/A N/A N/A
Provexis -69.30%-49.45%-56.14%

In the previous week, HaloSource's average media sentiment score of 0.00 equaled Provexis'average media sentiment score.

Company Overall Sentiment
HaloSource Neutral
Provexis Neutral

7.9% of Provexis shares are held by institutional investors. 11.8% of Provexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HaloSource has higher earnings, but lower revenue than Provexis. Provexis is trading at a lower price-to-earnings ratio than HaloSource, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HaloSourceN/AN/AN/A-£1.49N/A
Provexis£871.27K30.96-£619.15K-£0.02N/A

Summary

HaloSource and Provexis tied by winning 4 of the 8 factors compared between the two stocks.

How does HaloSource compare to Argent BioPharma?

HaloSource (LON:HALO) and Argent BioPharma (LON:MXC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

HaloSource has higher earnings, but lower revenue than Argent BioPharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HaloSourceN/AN/AN/A-£1.49N/A
Argent BioPharma£1.32M0.00-£17.02M-£1.66N/A

In the previous week, HaloSource's average media sentiment score of 0.00 equaled Argent BioPharma'saverage media sentiment score.

Company Overall Sentiment
HaloSource Neutral
Argent BioPharma Neutral

1.2% of Argent BioPharma shares are owned by institutional investors. 8.2% of Argent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
HaloSourceN/A N/A N/A
Argent BioPharma N/A N/A -58.96%

Summary

HaloSource and Argent BioPharma tied by winning 3 of the 6 factors compared between the two stocks.

How does HaloSource compare to Argent BioPharma?

Argent BioPharma (LON:RGT) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled HaloSource'saverage media sentiment score.

Company Overall Sentiment
Argent BioPharma Neutral
HaloSource Neutral

HaloSource has a net margin of 0.00% compared to Argent BioPharma's net margin of -1,967.38%. Argent BioPharma's return on equity of 279.26% beat HaloSource's return on equity.

Company Net Margins Return on Equity Return on Assets
Argent BioPharma-1,967.38% 279.26% -108.57%
HaloSource N/A N/A N/A

1.1% of Argent BioPharma shares are held by institutional investors. 17.8% of Argent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argent BioPharmaN/AN/A-£17.53M-£0.24N/A
HaloSourceN/AN/AN/A-£1.49N/A

Summary

Argent BioPharma beats HaloSource on 5 of the 7 factors compared between the two stocks.

How does HaloSource compare to Celadon Pharmaceuticals?

Celadon Pharmaceuticals (LON:CEL) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

10.7% of Celadon Pharmaceuticals shares are owned by institutional investors. 65.1% of Celadon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled HaloSource'saverage media sentiment score.

Company Overall Sentiment
Celadon Pharmaceuticals Neutral
HaloSource Neutral

HaloSource has lower revenue, but higher earnings than Celadon Pharmaceuticals. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than HaloSource, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celadon Pharmaceuticals£123.38K66.61-£4.97M-£7.98N/A
HaloSourceN/AN/AN/A-£1.49N/A

HaloSource has a net margin of 0.00% compared to Celadon Pharmaceuticals' net margin of -9,520.00%. HaloSource's return on equity of 0.00% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celadon Pharmaceuticals-9,520.00% -131.82% -34.40%
HaloSource N/A N/A N/A

Summary

Celadon Pharmaceuticals and HaloSource tied by winning 4 of the 8 factors compared between the two stocks.

How does HaloSource compare to InnovaDerma?

InnovaDerma (LON:IDP) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Company Net Margins Return on Equity Return on Assets
InnovaDermaN/A N/A N/A
HaloSource N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovaDerma£9.82M0.00N/A-£7.50N/A
HaloSourceN/AN/AN/A-£1.49N/A

In the previous week, InnovaDerma's average media sentiment score of 0.00 equaled HaloSource'saverage media sentiment score.

Company Overall Sentiment
InnovaDerma Neutral
HaloSource Neutral

Summary

InnovaDerma beats HaloSource on 2 of the 3 factors compared between the two stocks.

Get HaloSource News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HALO vs. The Competition

Export
MetricHaloSourcePharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£11.35M£12.57B£7.37B£2.54B
Dividend YieldN/A2.61%2.53%6.17%
P/E Ratio-6.98789.80272.60367.57
Price / SalesN/A762.12623.8383,481.74
Price / CashN/A96.7778.6227.89
Price / BookN/A11.8913.057.19
Net IncomeN/A£2.81B£3.47B£5.89B
7 Day Performance14.58%1.77%2.09%0.30%
1 Month Performance1.56%3.85%6.64%3.31%
1 Year PerformanceN/A6.56%25.02%22.13%

HaloSource Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HALO
HaloSource
N/AN/AN/AN/A£11.35MN/AN/A390
PXS
Provexis
N/AGBX 1.22
+10.8%		N/A+62.9%£28.60M£871.27KN/A4
MXC
Argent BioPharma
N/AN/AN/AN/A£9.65M£1.32MN/A5
RGT
Argent BioPharma
N/AN/AN/AN/A£8.31MN/AN/AN/A
CEL
Celadon Pharmaceuticals
N/AGBX 13.40
flat		N/AN/A£8.22M£123.38KN/A2,780

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HALO) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel